In early January 2026, Moderna filed for marketing authorization of its investigational seasonal influenza vaccine mRNA-1010 ...

The company submitted an application for a seasonal flu vaccine it believes to be a key growth driver in the years ahead.

Moderna, Inc. (NASDAQ:MRNA) today announced that it had voluntarily withdrawn the pending Biologics License Application (BLA) seeking approval for its COVID-19 and Influenza combination vaccine for ...

CD Bioparticles, a leading manufacturer and supplier of numerous drug delivery products and services, has announced the launch of an advanced animal mRNA vaccine platform to accelerate the development ...

CAMBRIDGE, Mass., August 28, 2025 – Raina Biosciences Inc., (“Raina”), an mRNA technology and therapeutics company, today announced the publication of data from its generative AI platform in Science.

YONGIN, South Korea, Sept. 22, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a leading South Korean pharmaceutical company, announced today that it has submitted an Investigational New Drug (IND) ...

This presentation explores cutting-edge artificial intelligence (AI) approaches for the rational design of nucleic acid therapeutics, including linear mRNA, circular RNA (circRNA), and small ...

– GEMORNA is world’s first generative AI platform purpose-built for mRNA design and optimization, demonstrating state-of-the-art performance across diverse mRNA therapeutic applications – – GEMORNA ...